Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | NAPEPLD | Q6IQ20 | 7/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709555 | 0.90 | GHSR (0.54) | GHSRALDH1A1LMNAMMP3 | |
| SCHEMBL1709669 | 0.89 | GHSR (0.54) | GHSRALDH1A1LMNARENGAA | |
| SCHEMBL10121851 | 0.89 | GHSR (0.56) | GHSRALDH1A1LMNASMN1; SMN2MMP3 | |
| SCHEMBL1709563 | 0.88 | GHSR (0.60) | GHSRALDH1A1LMNAGAAACHE | |
| SCHEMBL10122280 | 0.88 | GHSR (0.54) | GHSRALDH1A1LMNARENGAA | |
| SCHEMBL10121891 | 0.87 | GHSR (0.56) | GHSRALDH1A1LMNARENGAA | |
| SCHEMBL10122124 | 0.87 | GHSR (0.54) | GHSRALDH1A1LMNARENGAA | |
| SCHEMBL10121989 | 0.87 | GHSR (0.57) | GHSRLMNAGAAOPRK1CNR2 | |
| SCHEMBL1709615 | 0.86 | GHSR (0.61) | GHSRALDH1A1LMNARENGAA | |
| SCHEMBL10122116 | 0.86 | GHSR (0.54) | GHSRALDH1A1LMNAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885ALDH1A1 3182/4885LMNA 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.